These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32925716)

  • 1. Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.
    Li L; Ye J
    Medicine (Baltimore); 2020 Sep; 99(37):e21788. PubMed ID: 32925716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma.
    Iida N; Mizukoshi E; Yamashita T; Terashima T; Arai K; Seishima J; Kaneko S
    Int J Cancer; 2019 Nov; 145(10):2701-2711. PubMed ID: 30980680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
    Zhu C; Zhang C; Wang S; Xun Z; Zhang D; Lan Z; Zhang L; Chao J; Liang Y; Pu Z; Ning C; Sang X; Yang X; Wang H; Jiang X; Zhao H
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38844407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
    Liu X; Li S; Wang L; Ma K
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167230. PubMed ID: 38734322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Wu H; Zheng X; Pan T; Yang X; Chen X; Zhang B; Peng L; Xie C
    Int J Cancer; 2022 Oct; 151(8):1321-1334. PubMed ID: 35579980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
    Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
    World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
    Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M
    Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 11. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.
    Huo R; Chen Y; Li J; Xu Q; Guo J; Xu H; You Y; Zheng C; Chen Y
    Curr Oncol; 2023 Feb; 30(2):1818-1830. PubMed ID: 36826102
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Chen T; Ding R; Chen X; Lu Y; Shi J; Lü Y; Tang B; Zhang W; Ye C; Yuan M; Yang Z
    Bioengineered; 2021 Dec; 12(1):8233-8246. PubMed ID: 34592890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.
    Piñero F; Vazquez M; Baré P; Rohr C; Mendizabal M; Sciara M; Alonso C; Fay F; Silva M
    Ann Hepatol; 2019; 18(3):480-487. PubMed ID: 31023615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
    Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
    J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
    Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
    Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
    Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
    Peters BA; Wilson M; Moran U; Pavlick A; Izsak A; Wechter T; Weber JS; Osman I; Ahn J
    Genome Med; 2019 Oct; 11(1):61. PubMed ID: 31597568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
    Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
    Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.